Similar Search Results

Pharmaceutical regulation in Europe and its impact on corporate R&D

Eger, Stephan; Mahlich, Jörg C. - In: Health economics review 4 (2014) 23, pp. 1-9

Objectives: Many European countries regulate the markets for prescription drugs in order to cope with rising health expenditures. On the other hand, regulation distorts incentives to invest in pharmaceutical R&D. This study aims at empirically assessing the impact of regulation on pharmaceutical...

Persistent link: https://www.econbiz.de/10010526909

Decisions of persons, the pharmaceutical industry, and donors in disease contraction and recovery assuming virus mutation

Hausken, Kjell; Ncube, Mthuli - In: Health economics review 11 (2021) 1, pp. 1-14

Background: The article develops an eight-period game between N persons and a pharmaceutical company. The choices of a donor and Nature are parametric. Methods: Persons choose between safe and risky behavior, and whether or not to buy drugs. The pharmaceutical company chooses whether or not to...

Persistent link: https://www.econbiz.de/10012607230

Cardiovascular drug shortages in Lebanon : a broken heart

Khattar, Georges; Hallit, Jennifer; El Chamieh, Carolla; … - In: Health economics review 12 (2022) 1, pp. 1-2

For nearly 3 years now, Lebanon has been assailed by compounded crises. With the economic instability, the coronavirus pandemic, and the explosion of the Beirut Port on August 4, 2020; the fragile Lebanese healthcare system has found itself at massive risk of a catastrophic public health crisis...

Persistent link: https://www.econbiz.de/10013198765

Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? : a scenario analysis

Mahlich, Jörg C.; Bartol, Arne; Dheban, Srirangan - In: Health economics review 11 (2021) 1/4, pp. 1-10

Aim: The productivity of pharmaceutical research and development (R&D) investments is declining due to high failure rates in clinical research. Recently, the US Food and Drug Administration (FDA) acknowledged that adaptive designs can make drug development more efficient and less costly. Our...

Persistent link: https://www.econbiz.de/10012482980

The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Dintsios, C. M.; Beinhauer, I. - In: Health economics review 10 (2020) 7, pp. 1-25

Background: We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price … Health Insurance Funds. The analysis was conducted for all oncology pharmaceuticals that underwent the early benefit …. Further analyses should be performed when more oncology pharmaceuticals have passed the early benefit assessment. …

Persistent link: https://www.econbiz.de/10012291135

Benefit assessment in Germany : implications for price discounts

Theidel, Ulrike; Schulenburg, Johann-Matthias von der - In: Health economics review 6 (2016) 33, pp. 1-12

Background: The AMNOG regulation, introduced in 2011 in Germany, changed the game for new drugs. Now, the industry is required to submit a dossier to the GBA (the central decision body in the German sickness fund system) to show additional benefit. After granting the magnitude of the additional...

Persistent link: https://www.econbiz.de/10011586599

Implementing personalized medicine with asymmetric information on prevalence rates

Antoñanzas Villar, Fernando; Juárez-Castelló, Carmelo A. - In: Health economics review 6 (2016) 35, pp. 1-8

Although personalized medicine is becoming the new paradigm to manage some diseases, the economics of personalized medicine have only focused on assessing the efficiency of specific treatments, lacking a theoretical framework analyzing the interactions between pharmaceutical firms and healthcare...

Persistent link: https://www.econbiz.de/10011586604

Discrete-choice modelling of patient preferences for modes of drug administration

Tetteh, Ebenezer Kwabena; Morris, Steve; … - In: Health economics review 7 (2017) 26, pp. 1-14

The administration of (biologically-derived) drugs for various disease conditions involves consumption of resources that constitutes a direct monetary cost to healthcare payers and providers. An often ignored cost relates to a mismatch between patients’ preferences and the mode of drug...

Persistent link: https://www.econbiz.de/10011763276

Trajectories of prices in generic drug markets : what can we infer from looking at trajectories rather than average prices?

Trujillo, Antonio J.; Gutierrez, Jose C.; Garcia … - In: Health economics review 12 (2022) 1, pp. 1-12

Background: Well-functioning competitive markets are key to controlling generic drug prices. This is important since over 90% of all drugs sold in the US are generics. Recently, there have been examples of large price increases in the generic market. Methods: This paper examines price...

Persistent link: https://www.econbiz.de/10013329485

Direct and indirect savings from parallel imports in Sweden

Granlund, David - In: Health economics review 12 (2022) 1, pp. 1-14

EUR) per year. In total, parallel imports reduced the cost for on-patent pharmaceuticals by 4%. When discounts were …

Persistent link: https://www.econbiz.de/10013490959